학술논문
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
Document Type
Article
Author
Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Tubiana-Mathieu, Nicole; Cany, Laurent; Catala, Stéphanie; Khayat, David; Pauporté, Iris; Kramar, Andrew
Source
In Lancet Oncology July 2013 14(8):741-748
Subject
Language
ISSN
1470-2045